ABSTRACT
Background: Atorvastatin is prescribed for the primary and the secondary prevention of coronary artery diseases. A wide variation in inter-individual statin response suggests that genetic differences may contribute to this variation. This study investigated the association of ABCB1 [C3435T] and ABCC1 [G2012T] polymorphisms with clinical response to atorvastatin in Iranian primary hyperlipidemic patients
Methods: Individuals [n=179] with primary hypercholesterolemia were enrolled, and peripheral blood samples were collected. Genotyping of two polymorphisms were performed by amplification refractory mutation system PCR
Results: Following four weeks of treatment, a significant reduction of LDL-C was observed in variant groups [CT+TT] of ABCB1 [P=0.018] and wild-type group [GG] of ABCC1 genes [P=0.029]. Logistic regression analysis revealed a significant difference between male and female responses to 10 mg/day atorvastatin [P=0.004, odds ratio=0.2, CI 95%=0.06-0.6]
Conclusion: Our finding indicated that these polymorphisms may be attributed to LDL-C serum levels in the primary hypercholesterolemia patients receiving atorvastatin
ABSTRACT
Statins have been used for decades as a successful cholesterol-lowering class of medicines. Statins are widely prescribed for the primary and secondary prevention of coronary artery disease. They reduce cardiovascular risk and improve health outcomes in people with cardiovascular disease. Although statins are considered as a safe medicine and are well tolerated by patients, prediction of an individual patient's response to statin therapy remains unclear. Variation to statin therapy has been attributed to both environmental and genetic factors. In this review, a number of candidate genes that affect statin pharmacokinetics and pharmacodynamics are discussed. Moreover, the association of demographic factors with statin response in related studies is described. In this article we have reviewed the literature concerning pharmacogenetic studies on statin response. Thirty seven English-language clinical trials, prospective or retrospective human investigations, case series, case reports, published between 1998 to 2015, were evaluated. Based on these data, there are some candidate genes that have been established as affecting genes on statin efficacy and suggest that drug therapy, based on individuals' genetic makeup, may result in a clinically important reduction in variation of statin response